Osborne Clarke advised Sound Bioventures in a Series B2 financing round for VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation. The round was led by Sound Bioventures and further included the European Innovation Council (EIC) Fund and existing investors EQT Life Sciences, Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, InnovationQuarter and Libertatis Ergo Holding.
The proceeds from the financing will enable VarmX to obtain investigational new drug (IND) approval for its lead compound VMX-C001 and to complete preparations for the pivotal clinical trial, including large scale manufacturing.
The Osborne Clarke Corporate M&A team was led by Partner Herke van Hulst and included Senior Associate Wouter Kok, Associate Nick Staes and Saliha el Morabit.
Osborne Clarke has a market-leading international venture capital practice and is widely recognised as a leading European law firm for companies operating in the life science and healthcare sector team. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market.
Corporate communications and press contacts
Connect with one of our experts
